Carillon Tower: “Bristol-Myers Squibb (BMY) Entered Into Accelerated Share Repurchase Agreements”

Carillon Tower Advisers, an investment management firm, published its “Carillon Clarivest Capital Appreciation Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. At the start of the quarter, the Carillon ClariVest Capital Appreciation Fund (the “Fund”), as compared to the Russell 1000® Growth Index, was most overweight in the information technology and healthcare sectors and most underweight in communication services and real estate. At the end of the quarter, the portfolio remained the most overweight in information technology and healthcare and the most underweight in communication services and real estate. Within the universe of the Russell 1000 Growth Index, energy performed the best while communication services and materials lagged.  Try to spend some time taking a look at the fund’s top 5 holdings to be informed about their best picks for 2022.

In its Q1 2022 investor letter, Carillon Clarivest Capital Appreciation Fund mentioned Bristol-Myers Squibb Company (NYSE:BMY) and explained its insights for the company. Founded in 1887, Bristol-Myers Squibb Company (NYSE:BMY) is a New York, New York-based pharmaceutical industry company with a $163.9 billion market capitalization. Bristol-Myers Squibb Company (NYSE:BMY) delivered a 23.50% return since the beginning of the year, while its 12-month returns are up by 15.69%. The stock closed at $77.00 per share on June 30, 2022.

Here is what Carillon Clarivest Capital Appreciation Fund has to say about Bristol-Myers Squibb Company (NYSE:BMY) in its Q1 2022 investor letter: 

“Stock selection contributed the most while sector allocation was also positive. An underweight to communication services and an overweight to energy helped performance, while an underweight to consumer staples and an overweight to materials detracted. Stock selection was strong within healthcare and materials but was weak within information technology and industrials. Bristol-Myers Squibb (NYSE:BMY), the biopharmaceutical company, entered into accelerated share repurchase agreements.”

Our calculations show that Bristol-Myers Squibb Company (NYSE:BMY) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Bristol-Myers Squibb Company (NYSE:BMY) was in 70 hedge fund portfolios at the end of the first quarter of 2022, compared to 66 funds in the previous quarter. Bristol-Myers Squibb Company (NYSE:BMY) delivered a 5.44% return in the past 3 months.

In March 2022, we also shared another hedge fund’s views on Bristol-Myers Squibb Company (NYSE:BMY) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q1 page.

Disclosure: None. This article is originally published at Insider Monkey.